title: Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
abstract: OBJECTIVE
  To compare the efficacy of infliximab (IFX) on refractory uveoretinitis between Behçet disease (BD) patients with short duration (≤18 months, n = 6) versus long duration (>18 months, n = 7) of their ocular disease.
  
  
  METHODS
  Records of 13 BD patients treated with IFX for 24 months were retrospectively reviewed.
  
  
  RESULTS
  Frequency of ocular attacks decreased with IFX treatment in both groups, with no significant difference. Retinal and disc vascular leakage scores also decreased in both groups, however was significantly lower in the short-duration group. Percentage of eyes with a best-corrected visual acuity (BCVA) of 1.0 or better at year 2 was 100% in the short-duration and 21% in the long-duration group.
  
  
  CONCLUSIONS
  Induction of early remission using IFX appeared to be more effective in reducing background vascular leakage and in maintaining good visual acuity in BD patients.
authors: a Department of Ophthalmology , Kyorin University School of Medicine , Tokyo , Japan.
authors: Hiroshi
authors: H
authors: Keino
authors: a Department of Ophthalmology , Kyorin University School of Medicine , Tokyo , Japan.
authors: Annabelle A
authors: AA
authors: Okada
authors: a Department of Ophthalmology , Kyorin University School of Medicine , Tokyo , Japan.
authors: Takayo
authors: T
authors: Watanabe
authors: a Department of Ophthalmology , Kyorin University School of Medicine , Tokyo , Japan.
authors: Makiko
authors: M
authors: Nakayama
authors: a Department of Ophthalmology , Kyorin University School of Medicine , Tokyo , Japan.|b Department of Ophthalmology , Toyama University School of Medicine , Toyama , Japan.
authors: Tomoko
authors: T
authors: Nakamura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012173:Retinitis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D000069285:Infliximab
keywords: BOS24; Behçet disease; fluorescein angiography; infliximab; uveoretinitis